
Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More
Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a […]